Phase II studies: wrong doses, wrong patients?
Judson
I R
IR
Drug Development Section, Institute of Cancer Research, Belmont, Sutton, Surrey, U.K.
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood; D004334:Drug Administration Schedule; D004341:Drug Evaluation / Q000379:methods; D004351:Drug Resistance; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D011379:Prognosis
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor